Table 4.
rs9642880 | Associations | Risk assessment | |||||
---|---|---|---|---|---|---|---|
GT | TT | aP. value | OR | 95% C.I | bP. value | ||
n=9 | n=51 | ||||||
Sex | Female | 3 (33.3%) | 12 (23.5%) | 0.02* | 1.09 | 0.969 - 1.226 | 0.1 |
Male | 6 (66.7%) | 39 (76.5%) | |||||
Bilhariziasis | Negative | 3 (33.3%) | 18 (35.3%) | 0.6 | 0.917 | 0.204 - 4.109 | 0.9 |
Positive | 6 (66.7%) | 33 (64.7%) | |||||
Smoker | No | 3 (33.3%) | 15 (29.4%) | 0.5 | 1.2 | 0.265 - 5.438 | 0.8 |
Yes | 6 (66.7%) | 36 (70.6%) | |||||
Clinical Ex. | T1 | 0 (0.0%) | 6 (11.8%) | 0.2 | - | - | - |
T2 | 6 (66.7%) | 21 (41.2%) | 0.01* | 3.5 | 1.413 - 8.672 | 0.01* | |
T3 | 3 (33.3%) | 24 (47.1%) | 0.001** | 8 | 2.409 - 26.567 | 0.001** | |
Cytology | Negative | 6 (66.7%) | 15 (29.4%) | 0.03* | 4.8 | 1.059 - 21.753 | 0.04* |
Positive | 3 (33.3%) | 36 (70.6%) | |||||
Histopathological characteristics |
Scc | 3 (33.3%) | 15 (29.4%) | 0.5 | 1.2 | 0.265 - 5.438 | 0.8 |
UC | 6 (66.7%) | 36 (70.6%) | |||||
Stage | NMIBC | 0 (0.0%) | 3 (5.9%) | 0.4 | - | - | - |
MIBC | 9 (100.0%) | 42 (82.4%) | 0.02* | 1.667 | 2.272 - 7.587 | 0.1 | |
Superficial bladder cancer | 0 (0.0%) | 6 (11.8%) | 0.2 | - | - | - | |
Serum Creatinine | Normal | 6 (66.7%) | 39 (76.5%) | 0.4 | 0.615 | 0.133 - 2.841 | 0.5 |
High | 3 (33.3%) | 12 (23.5%) | |||||
Lymph Node | Negative | 0 (0.0%) | 27 (52.9%) | 0.03* | 0.111 | 0.013 - 0.954 | 0.06 |
Positive | 9 (100.0%) | 24 (47.1%) | |||||
Tumor Grade | GI | 0 (0.0%) | 6 (11.8%) | 0.2 | - | - | - |
GII | 3 (33.3%) | 15 (29.4%) | 0.4 | 1.035 | 1.448 - 10.271 | 0.5 | |
GIII | 6 (66.7%) | 30 (58.8%) | 0.1 | 1.123 | 2.081 - 8.013 | 0.2 |
SCC, squamous cell carcinoma; TCC, non-papillary transitional cell carcinoma; Ta, Superficial bladder cancer; NMIBC, Non muscle invasive bladder cancer; MIBC, Muscle invasive bladder cancer; OR, Odds Ratio; CI, Confidence Interval; *P value ≤ 0.05 significant; **P value ≤ 0.01 highly significant; aP. Value is depending on the X2 test, while bP. Value is depending onLogistic Regression analysis.